Published in
Wiley, Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 4S_Part_12(8), 2012
DOI: 10.1016/j.jalz.2012.05.1161
Wiley, Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 4S_Part_23(7), 2011
DOI: 10.1016/j.jalz.2011.09.010
Wiley Open Access, EMBO Molecular Medicine, 7(4), p. 647-659, 2012
Links
- ORCID
- ORCID
- Wiley | PDF
- Wiley | PDF
- Wiley Open Access | PDF
- [europepmc.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.researchgate.net] | PDF
Tools
Novel APP/Aβ mutation K16N produces highly toxic heteromeric Aβ oligomers
,
Peter W. Hildebrand,
Dietmar Schmitz ,
Michael Schaefer,
Rudi Lurz,
Sabine Skodda,
Raina Yamamoto,
Sönke Arlt,
Ulrich Finckh
and other authors.
Full text: Download
Abstract
Here, we describe a novel missense mutation in the amyloid precursor protein (APP) causing a lysine-to-asparagine substitution at position 687 (APP770; herein, referred to as K16N according to amyloid-β (Aβ) numbering) resulting in an early onset dementia with an autosomal dominant inheritance pattern. The K16N mutation is located exactly at the α-secretase cleavage site and influences both APP and Aβ. First, due to the K16N mutation APP secretion is affected and a higher amount of Aβ peptides is being produced. Second, Aβ peptides carrying the K16N mutation are unique in that the peptide itself is not harmful to neuronal cells. Severe toxicity, however, is evident upon equimolar mixture of wt and mutant peptides, mimicking the heterozygous state of the subject. Furthermore, Aβ42 K16N inhibits fibril formation of Aβ42 wild-type. Even more, Aβ42 K16N peptides are protected against clearance activity by the major Aβ-degrading enzyme neprilysin. Thus the mutation characterized here harbours a combination of risk factors that synergistically may contribute to the development of early onset Alzheimer disease.